Literature DB >> 19225920

Current status and perspectives of brachytherapy for cervical cancer.

Takafumi Toita1.   

Abstract

Standard definitive radiotherapy for cervical cancer consists of whole pelvic external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT). In Japan, high-dose-rate ICBT (HDR-ICBT) has been utilized in clinical practice for more than 40 years. Several randomized clinical trials demonstrated that HDR-ICBT achieved comparative outcomes, both for pelvic control and incidences of late complications, to low-dose-rate (LDR) ICBT. In addition, HDR-ICBT has some potential advantages over LDR-ICBT, leading to further improvement in treatment results. Prior to the current computer planning systems, some excellent treatment planning concepts were established. At present, systems modified from these concepts, or novel approaches, such as image-guided brachytherapy (IGBT) are under investigation. One serious problem to be solved in HDR-ICBT for cervical cancer is that of the discrepancy in standard treatment schedules for combination HDR-ICBT and EBRT between the United States and Japan. Prospective studies are ongoing to assess the efficacy and toxicity of the Japanese schedule.

Entities:  

Mesh:

Year:  2009        PMID: 19225920     DOI: 10.1007/s10147-008-0865-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  37 in total

1.  The American brachytherapy society survey of brachytherapy practice for carcinoma of the cervix in the United States.

Authors:  S Nag; C Orton; D Young; B Erickson
Journal:  Gynecol Oncol       Date:  1999-04       Impact factor: 5.482

2.  The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix.

Authors:  S Nag; B Erickson; B Thomadsen; C Orton; J D Demanes; D Petereit
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

3.  Patterns of radiotherapy practice for patients with squamous carcinoma of the uterine cervix: patterns of care study.

Authors:  P J Eifel; J Moughan; J Owen; A Katz; I Mahon; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-15       Impact factor: 7.038

4.  Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.

Authors:  Shang-Wen Chen; Ji-An Liang; Yao-Ching Hung; Lian-Shung Yeh; Wei-Chun Chang; Wu-Chou Lin; Shih-Neng Yang; Fang-Jen Lin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-18       Impact factor: 7.038

5.  Patterns of radiotherapy practice for patients with cervical cancer (1999-2001): patterns of care study in Japan.

Authors:  Takafumi Toita; Takeshi Kodaira; Atsunori Shinoda; Takashi Uno; Yuichi Akino; Michihide Mitsumori; Teruki Teshima
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-01-11       Impact factor: 7.038

6.  High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence--the University of Wisconsin experience.

Authors:  D G Petereit; J N Sarkaria; D M Potter; J C Schink
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-12-01       Impact factor: 7.038

7.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.

Authors:  C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

8.  A simple method of obtaining equivalent doses for use in HDR brachytherapy.

Authors:  S Nag; N Gupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

9.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

Authors:  Rachelle Lanciano; Alison Calkins; Brian N Bundy; Groesbeck Parham; Joseph A Lucci; David H Moore; Bradley J Monk; Dennis M O'Connor
Journal:  J Clin Oncol       Date:  2005-10-17       Impact factor: 44.544

10.  Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.

Authors:  Hans-Georg Strauss; Thomas Kuhnt; Cornelia Laban; Daniela Puschmann; Steffi Pigorsch; Juergen Dunst; Heinz Koelbl; Gabriele Haensgen
Journal:  Strahlenther Onkol       Date:  2002-07       Impact factor: 3.621

View more
  7 in total

Review 1.  Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers.

Authors:  Jesse B Wolinsky; Yolonda L Colson; Mark W Grinstaff
Journal:  J Control Release       Date:  2011-12-01       Impact factor: 9.776

2.  Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.

Authors:  Takafumi Toita; Shingo Kato; Satoshi Ishikura; Kayoko Tsujino; Takeshi Kodaira; Takashi Uno; Kazuo Hatano; Hideyuki Sakurai; Yuzuru Niibe; Tomoko Kazumoto; Tetsuo Nishimura; Ryo Kitagawa; Miki Fukutani; Masahiko Oguchi; Kenji Umayahara; Yasuyuki Hirashima; Yoichi Aoki; Ken Takizawa
Journal:  Int J Clin Oncol       Date:  2011-02-18       Impact factor: 3.402

3.  Dosimetric feasibility of computed tomography-based image-guided brachytherapy in locally advanced cervical cancer: a Japanese prospective multi-institutional study.

Authors:  Yuki Otani; Tatsuya Ohno; Ken Ando; Kazutoshi Murata; Shingo Kato; Shin-Ei Noda; Keiko Murofushi; Hiroki Ushijima; Daisaku Yoshida; Noriyuki Okonogi; Fumiaki Isohashi; Masaru Wakatsuki; Takashi Nakano
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

Review 4.  Müllerian duct anomalies and their effect on the radiotherapeutic management of cervical cancer.

Authors:  Madhup Rastogi; Swaroop Revannasiddaiah; Pragyat Thakur; Priyanka Thakur; Manish Gupta; Manoj K Gupta; Rajeev K Seam
Journal:  Chin J Cancer       Date:  2013-02-19

5.  The usefulness of an independent patient-specific treatment planning verification method using a benchmark plan in high-dose-rate intracavitary brachytherapy for carcinoma of the uterine cervix.

Authors:  Yutaka Takahashi; Masahiko Koizumi; Iori Sumida; Fumiaki Isohashi; Toshiyuki Ogata; Yuichi Akino; Yasuo Yoshioka; Shintaro Maruoka; Shinichi Inoue; Koji Konishi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-07-17       Impact factor: 2.724

6.  Impact of boost irradiation on pelvic lymph node control in patients with cervical cancer.

Authors:  Masaru Wakatsuki; Tatsuya Ohno; Shingo Kato; Ken Ando; Shin-Ei Noda; Hiroki Kiyohara; Kei Shibuya; Kumiko Karasawa; Tadashi Kamada; Takashi Nakano
Journal:  J Radiat Res       Date:  2013-08-02       Impact factor: 2.724

7.  Radiation therapy for stage IVA uterine cervical cancer: treatment outcomes including prognostic factors and risk of vesicovaginal and rectovaginal fistulas.

Authors:  Masaharu Hata; Izumi Koike; Etsuko Miyagi; Reiko Numazaki; Mikiko Asai-Sato; Hisashi Kaizu; Yuki Mukai; Shoko Takano; Eiko Ito; Madoka Sugiura; Tomio Inoue
Journal:  Oncotarget       Date:  2017-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.